Galecto, Inc. (GLTO)
NASDAQ: GLTO · Real-Time Price · USD
6.73
-0.10 (-1.46%)
Nov 4, 2024, 4:00 PM EST - Market closed

Company Description

Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases.

The company’s lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis.

It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis.

Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.

Galecto, Inc.
Galecto logo
Country Denmark
Founded 2011
IPO Date Oct 29, 2020
Industry Biotechnology
Sector Healthcare
Employees 13
CEO Hans Schambye

Contact Details

Address:
Ole Maaloes Vej 3, Copenhagen N
Copenhagen, 2200
Denmark
Phone 45 70 70 52 10
Website galecto.com

Stock Details

Ticker Symbol GLTO
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $15.00
CIK Code 0001800315
CUSIP Number 36322Q107
ISIN Number US36322Q1076
Employer ID 37-1957007
SIC Code 2834

Key Executives

Name Position
Dr. Hans T. Schambye M.D., Ph.D. Co-Founder, President, Chief Executive Officer and Director
Garrett Winslow Esq. Senior Vice President, General Counsel and Corporate Secretary
Ulf J. Nilsson Co-Founder
Dr. Hakon Leffler Co-Founder
Prof. Tariq Sethi B.Sc., FRCP, M.A., M.D., Ph.D. Co-Founder
Lori C. Firmani Interim Chief Financial Officer

Latest SEC Filings

Date Type Title
Nov 1, 2024 10-Q Quarterly Report
Oct 15, 2024 8-K Current Report
Oct 7, 2024 8-K Current Report
Sep 18, 2024 8-K Current Report
Sep 11, 2024 8-K Current Report
Sep 5, 2024 8-K Current Report
Aug 29, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Aug 12, 2024 10-Q Quarterly Report
Jun 24, 2024 SC 13D/A [Amend] General statement of acquisition of beneficial ownership
Jun 21, 2024 8-K Current Report